XOMA Royalty Corp 8K

Ligand Pharmaceuticals completed its all-cash acquisition of XOMA Royalty Corporation, with XOMA shareholders receiving $39.00 per share plus CVRs and XOMA’s Nasdaq listing terminated.

XOMA Royalty Corporation announced that Ligand Pharmaceuticals Incorporated has closed its previously announced acquisition of XOMA Royalty, under which Ligand acquired all outstanding shares of XOMA Royalty common stock for $39.00 in cash per share and granted stockholders and equity award holders one non-transferable contingent value right (CVR) per share tied to 75% of the net proceeds from certain pending litigation, resulting in XOMA Royalty’s common stock ceasing to trade on the Nasdaq stock exchange.

Filing Facts

CIK

791908

Ticker

XOMA

Form

8K

Source Type

fda

Accession

0001193125-26-302648

Alert Tier

8